Torbjørn Omland1, James A de Lemos2, Oddgeir L Holmen3, Håvard Dalen4, Jūratė Šaltytė Benth5, Ståle Nygård6, Kristian Hveem3, Helge Røsjø7. 1. Division of Medicine and Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre and torbjorn.omland@medisin.uio.no. 2. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX; 3. HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway; 4. Department of Medicine, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway; MI Laboratory and Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; 5. Institute of Clinical Medicine, University of Oslo, Oslo, Norway; HØKH Research Centre, Akershus University Hospital, Lørenskog, Norway; 6. Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre and Institute for Experimental Medical Research and Bioinformatics Core Facility, Institute for Medical Informatics, Oslo University Hospital and University of Oslo, Oslo, Norway. 7. Division of Medicine and Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre and.
Abstract
BACKGROUND: A new, high-sensitivity assay for cardiac troponin I (hs-cTnI) permits evaluation of the prognostic value of cardiac troponins within the reference interval. Men have higher hs-cTnI concentrations than women, but the underlying pathophysiological mechanisms and prognostic implications are unclear. The aim of this study was to assess the potential impact of sex on the association between hs-cTnI and cardiovascular death. METHODS: By use of the Architect STAT High-Sensitive Troponin assay, we measured hs-cTnI in 4431 men and 5281 women aged ≥20 years participating in the prospective observational Nord-Trøndelag Health Study (HUNT). RESULTS: hs-cTnI was detectable in 98.5% of men and 94.7% of women. During a mean follow-up period of 13.9 years, 708 cardiovascular deaths were registered. hs-cTnI was associated with the incidence of cardiovascular death [adjusted hazard ratio (HR) per 1 SD in log hs-cTnI 1.23 (95% CI 1.15-1.31)], with higher relative risk in women than men [HR 1.44 (1.31-1.58) vs 1.10 (1.00-1.20); Pinteraction < 0.001]. This finding was mediated by both lower risk associated with low hs-cTnI concentrations in women than in men and higher risk associated with high concentrations of hs-cTnI in women than in men. Male sex was associated with a higher risk of cardiovascular death [HR 1.28 (1.11-1.49)], but after adjustment for hs-cTnI, this association disappeared [HR 0.87 (0.75-1.02)]. CONCLUSIONS: The prognostic value of hs-cTnI concentrations in the general population is stronger in women than in men. Subtle impairment of cardiovascular status may contribute to higher hs-cTnI concentrations in men, reflecting sex-dependent differences in cardiovascular risk.
BACKGROUND: A new, high-sensitivity assay for cardiac troponin I (hs-cTnI) permits evaluation of the prognostic value of cardiac troponins within the reference interval. Men have higher hs-cTnI concentrations than women, but the underlying pathophysiological mechanisms and prognostic implications are unclear. The aim of this study was to assess the potential impact of sex on the association between hs-cTnI and cardiovascular death. METHODS: By use of the Architect STAT High-Sensitive Troponin assay, we measured hs-cTnI in 4431 men and 5281 women aged ≥20 years participating in the prospective observational Nord-Trøndelag Health Study (HUNT). RESULTS: hs-cTnI was detectable in 98.5% of men and 94.7% of women. During a mean follow-up period of 13.9 years, 708 cardiovascular deaths were registered. hs-cTnI was associated with the incidence of cardiovascular death [adjusted hazard ratio (HR) per 1 SD in log hs-cTnI 1.23 (95% CI 1.15-1.31)], with higher relative risk in women than men [HR 1.44 (1.31-1.58) vs 1.10 (1.00-1.20); Pinteraction < 0.001]. This finding was mediated by both lower risk associated with low hs-cTnI concentrations in women than in men and higher risk associated with high concentrations of hs-cTnI in women than in men. Male sex was associated with a higher risk of cardiovascular death [HR 1.28 (1.11-1.49)], but after adjustment for hs-cTnI, this association disappeared [HR 0.87 (0.75-1.02)]. CONCLUSIONS: The prognostic value of hs-cTnI concentrations in the general population is stronger in women than in men. Subtle impairment of cardiovascular status may contribute to higher hs-cTnI concentrations in men, reflecting sex-dependent differences in cardiovascular risk.
Authors: Jeanney Lew; Monika Sanghavi; Colby R Ayers; Darren K McGuire; Torbjørn Omland; Dorothee Atzler; Maria O Gore; Ian Neeland; Jarett D Berry; Amit Khera; Anand Rohatgi; James A de Lemos Journal: Circulation Date: 2017-02-07 Impact factor: 29.690
Authors: Xiaoming Jia; Wensheng Sun; Ron C Hoogeveen; Vijay Nambi; Kunihiro Matsushita; Aaron R Folsom; Gerardo Heiss; David J Couper; Scott D Solomon; Eric Boerwinkle; Amil Shah; Elizabeth Selvin; James A de Lemos; Christie M Ballantyne Journal: Circulation Date: 2019-04-29 Impact factor: 29.690
Authors: Christopher W Puleo; Colby R Ayers; Sonia Garg; Ian J Neeland; Alana A Lewis; Ambarish Pandey; Mark H Drazner; James A de Lemos Journal: Biomark Med Date: 2021-10-19 Impact factor: 2.851
Authors: Nicholas A Marston; Marc P Bonaca; Petr Jarolim; Erica L Goodrich; Deepak L Bhatt; Philippe G Steg; Marc Cohen; Robert F Storey; Per Johanson; Stephen D Wiviott; Eugene Braunwald; Marc S Sabatine; David A Morrow Journal: JAMA Cardiol Date: 2020-11-01 Impact factor: 14.676
Authors: Fjola D Sigurdardottir; Magnus N Lyngbakken; Kristian Hveem; Harald Hrubos Strøm; Helge Røsjø; Susan Redline; Torbjørn Omland Journal: J Sleep Res Date: 2021-02-24 Impact factor: 5.296